Evidence map›Paper›PMID 38951335›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Protein Production at the 100L Scale.

Sneha Rangarajan, Grace von Berg, Heather Allen, Carter Mitchell

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sneha RangarajanKemp Proteins, Frederick, MD, USA. Sneha.rangarajan@kempproteins.com.
Grace von BergKemp Proteins, Frederick, MD, USA.
Heather AllenKemp Proteins, Frederick, MD, USA.
Carter MitchellKemp Proteins, Frederick, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Baculovirus Expression Vector System (BEVS) has revolutionized the field of recombinant protein expression by enabling efficient and high yield production. The platform offers many advantages including manufacturing speed, flexible design, and scalability. In this chapter, we describe the methods including strategies and considerations to successfully optimize and scale-up using BEVS as a tool for production (Fig. 1). As an illustrative case study, we present an example focused on the production of a viral glycoprotein.

Indexed as

BaculoviridaeGenetic VectorsRecombinant ProteinsAnimalsHumansSf9 CellsRecombinant ProteinsBaculovirus expression vector system (BEVS)High titer stock (HTS)Hours post infection (hpi)Initial virus seed stock (P0)Insect cell cultureOptimizationProtein expressionScale-upStirred tank reactor (STR)

Identifiers

PMID38951335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.